JAMP Pharma Group Receives Health Canada Approval for PrJAMP Sitagliptin, a New Generic Alternative for the Treatment of Type 2 Diabetes

  • JAMP Pharma Group received marketing approval for Sitagliptin, offering a more cost-effective alternative to the reference product Januvia® (marketed by Merck Canada Inc.).

  • The JAMP Pharma group, a leader in product launches1is expanding its line of diabetes treatment products, moving it closer to achieving its goal of providing healthcare professionals and patients with better access to high-quality medicines.

  • The JAMP Pharma group, founded in Canada since 1988, it has contributed to the country’s economic growth and helped build a future in which all Canadians can live full and healthy lives.

BOUCHERVILLE,QC, January 6, 2023 /CNW Telbec/ – The JAMP Pharma Group, a Canadian pharmaceutical company headquartered in the Montreal region, is pleased to announce the approval of Health Canada prJAMP Sitagliptin, a generic alternative to the reference product Januvia® from Merck Canada Inc. prJAMP Sitagliptin, to be available soon, is indicated for use as an adjunct to diet and exercise to improve glycemic control in adult patients with type 2 diabetes mellitus for whom metformin is inappropriate due to contraindications or intolerance. When the actual treatment, associated with diet and exercise, does not result in adequate glycemic control, prJAMP Sitagliptin is also indicated in combination with metformin, metformin and a sulphonylurea, pioglitazone (alone or with metformin), or premixed or long/intermediate-acting insulin (alone or with metformin).

“We are proud to start the year with the approval of Sitagliptin, a key molecule for patients with type 2 diabetes widely used in Canada. This approval will allow us to continue our mission to offer Canadians more convenient pharmaceutical options. Our generics offering now includes more than 300 molecules across all therapeutic fields,” says Bruno Mäder, President and Chief Operating Officer of JAMP Pharma Group. “The addition of sitagliptin to our product portfolio further demonstrates our expertise in the product launches and our leadership in the generics industry. market.”

It has been estimated that by 2021, approximately 10% of Canadians will have been diagnosed with type 1 or type 2 diabetes, or nearly 3,900,000 patients. The direct costs to the Canadian healthcare system were $3.8 billion in this same year2. The introduction of this generic alternative, of equal quality, but cheaper, will allow more patients to access this therapy and lead to significant savings for drug insurance plans.

JAMP Pharma will offer this product in bottles containing 30, 100 and 500 (100 mg) tablets and 1000 (25 mg and 50 mg) tablets. More formats will be added soon.

Strengths and formats offered:

Sitagliptin 25 mg: bottles containing 1000 tablets. Bottles containing 100 tablets will be available soon.

Sitagliptin 50 mg: bottles containing 1000 tablets. Bottles containing 100 tablets will be available soon.

Sitagliptin 100 mg: bottles containing 30, 100 and 500 tablets.

About JAMP Pharma Group

JAMP Pharma Group is headquartered in Canada with headquarters in Montreal area. Having experienced exceptional growth over the past 10 years, JAMP Pharma Group is present in all segments of the pharmaceutical market with a portfolio of over 300 molecules and is one of the industry leaders in terms of annual prescription volume3. Additionally, with nearly 40 new products cleared for sale by Health Canada in the past year, JAMP Pharma Group is Canada’s leader in product launches, enhancing new treatment options available in Canada, including many specialty drugs. The group also has its Swiss brands Wampole-Laboratory, Orimed Pharma and BIOJAMP, also offering 180 over-the-counter products with a wide range of vitamins, supplements and natural products, as well as prescription and branded products and value-added biosimilar products. The JAMP Care Patient Support Program is designed to assist patients, as well as healthcare professionals, in taking specialty medicines and biosimilars offered by the JAMP Pharma group.

1Source: Pharmaceutical manufacturers with the highest volume of product launches in Canada between 2016 and 2022. Based in part on data obtained under license from IQVIA Solutions Canada Inc., for the following information service: CDH, MAT, January 2016 to December 2022 All rights reserved. This statement is not necessarily that of IQVIA Solutions Canada Inc. or any of its affiliates or subsidiaries.

2 Source: Diabetes Canada: https://www.diabetes.ca/DiabetesCanadaWebsite/media/Advocacy-and-Policy/Backgrounder/2021_Backgrounder_Canada_English_FINAL.pdf

3 Source: Pharmaceutical manufacturers with the highest volume of product launches reported in Canada between August 2008 And September 2022. Based in part on data licensed from IQVIA Solutions Canada for the following service: CDH, MAT 2016/01 to 2022/12. All rights reserved. This statement is not necessarily that of IQVIA Solutions Canada Inc. or any of its affiliates or subsidiaries.

LinkedIn: JAMP Pharma Group

SOURCE JAMP Pharma

cision

See original content: http://www.newswire.ca/en/releases/archive/January2023/06/c8843.html

Leave a Comment

Your email address will not be published. Required fields are marked *